Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer death worldwide. However, molecular genetics underlying HCC development remain to be poorly understood. Treatment options for HCC are very limited and in general ineffective. There is only a single option for treatment of advanced HCC (Sorafenib) which prolongs life by an average of just three months! Consequently, there is a pressing unmet need for new insights on HCC that will lead to new therapies. The growing understanding of molecular pathogenesis of HCC, on the other hand, does open the door for novel strategy of targeted therapy. Hydrodynamic transfection combines hydrodynamic injection together with sleeping beauty mediated somatic integration for long term gene expression. Because of its flexibility and high efficiency, it has now becoming increasingly popular to be used to generate murine models for studying hepatocarcinogenesis. However, so far few inducible systems have been established for this technology. Amplification and overexpression of c-Myc oncogene is one of the most frequently observed genetic events during HCC pathogenesis; and c-Myc is considered to be an important driver oncogene for HCC. Indeed overexpression of c-Myc in mouse liver promotes the formation of poorly differentiated HCC. Recently, we discovered that ablation of Raptor, the unique component of mTORC1, significantly suppressed c-Myc driven HCC development in vivo. However, it is not clear whether mTORC1 is required for c-Myc HCC maintenance and whether inhibition of mTORC1 leads to HCC regression. In this application, we hypothesize that mTORC1 is required for c-Myc maintenance; and deleting Raptor after tumor formation will lead to tumor regression. In this R03 small application, we will establish an efficient inducible Cre system for hydrodynamic transfection (Aim 1). We will then apply the technology to delete Raptor in c-Myc induced HCC tumors in vivo with the goal to study whether mTORC1 complex is required for maintaining c-Myc HCC (Aim 2). Altogether, this is a self-contained research projects which fits well with the description and scope of a R03 small research project. It assists to develop a powerful research technology which can be used to characterize the requirement of a gene or pathway for HCC maintenance. The results from such studies are critical for establishing the gene or pathway for the treatment of HCC.
Liver cancer is a deadly disease with no effective treatment options. In this application, we plan to develop a novel mouse liver tumor model which allows us to delete a gene after tumor formation with the goal to determine whether the gene is required for maintaining liver tumor growth in vivo. Our study is likely to provide new targets for the treatment of liver cancer.
